Optimizing Skyrizi Prior Authorization for Hospitalist Settings

Navigating Skyrizi prior authorization for hospitalist teams presents unique challenges, often requiring swift action to ensure continuity of care or appropriate discharge planning.

Hospitalists manage complex patient populations, frequently encountering specialty medications like Skyrizi (risankizumab) for conditions such as Crohn's disease or psoriatic arthritis. The urgency of inpatient care, coupled with the rigorous documentation demands for IL-23 inhibitors, necessitates an efficient prior authorization workflow to prevent delays in treatment or post-acute placement.

Skyrizi in the Hospitalist Clinical Pathway

While typically managed in outpatient settings for chronic conditions like plaque psoriasis, psoriatic arthritis, and Crohn's disease, hospitalists may encounter patients requiring Skyrizi (risankizumab) for acute exacerbations or as part of a complex discharge plan. Decisions to initiate or continue this IL-23 inhibitor in an inpatient setting are guided by specialty-specific criteria, often after failure of conventional therapies, aligning with guidelines from bodies like the American College of Gastroenterology (ACG) or American College of Rheumatology (ACR).

Key Documentation for Skyrizi PA Approval

Detailed clinical notes outlining diagnosis, disease severity (e.g., CDAI for Crohn's, PASI/BSA for psoriasis, DAS28 for psoriatic arthritis), and current symptoms.
Documentation of prior therapeutic failures or contraindications to alternative treatments (e.g., anti-TNF agents, conventional DMARDs).
Relevant diagnostic test results, including imaging, endoscopy reports, and laboratory markers (e.g., CRP, ESR, fecal calprotectin).
Comprehensive medication history and current treatment plan, including rationale for Skyrizi.
Discharge plan detailing where and how subsequent doses will be administered, if applicable.

Adhering to Clinical Guidelines for Risankizumab

Payer medical policies for risankizumab (Skyrizi) are closely tied to established clinical guidelines. For Crohn's disease, hospitalists must demonstrate alignment with ACG guidelines, often requiring evidence of moderate-to-severe disease activity and failure of or intolerance to other biologics. Similarly, for psoriatic arthritis, adherence to ACR recommendations, including documentation of active disease despite conventional synthetic DMARDs, is critical for PA approval.

Common Denial Reasons for Inpatient Skyrizi PA

Lack of documented failure of preferred first-line or step-therapy agents as per payer policy.
Insufficient clinical evidence or severity criteria met for the specific indication in the inpatient setting.
Incomplete submission of supporting diagnostic test results or clinical notes.
Absence of a clear, medically necessary rationale for inpatient initiation or administration of Skyrizi.
Discrepancy between the requested site of care (inpatient) and payer's preferred outpatient infusion network.

Automating Specialty Drug Prior Authorizations for Acute Care

Managing prior authorizations for specialty drugs like Skyrizi adds significant administrative burden to hospitalist teams already navigating high-volume PA categories such as post-acute placement and observation status. Klivira's platform automates the submission of X12 278 transactions, leveraging EMR data via SMART on FHIR integration to pre-populate forms and accelerate the ePA process. This reduces manual effort, minimizes errors, and helps ensure timely access to critical therapies for inpatient populations.

Frequently asked questions

How does Klivira handle urgent Skyrizi PAs for acute exacerbations in the inpatient setting?

Klivira's platform is designed to expedite urgent prior authorizations by streamlining data extraction from EMRs and facilitating rapid submission via X12 278 or direct payer portal integration. This reduces manual touchpoints and accelerates the review process, critical for time-sensitive inpatient treatments.

What specific EMR data points are critical for a successful Skyrizi PA submission for hospitalists?

Key data points include diagnosis codes (ICD-10), detailed clinical notes on disease severity and progression, medication history, lab results (e.g., CRP, ESR, imaging reports), and documentation of previous treatment failures. Klivira's EMR integration ensures these data points are accurately captured and transmitted.

Are hospitalists typically responsible for initial Skyrizi PAs or renewals, and how does Klivira support both?

Hospitalists primarily manage initial PAs for new diagnoses or acute exacerbations requiring inpatient treatment, as well as ensure continuity of care for patients already on Skyrizi. Klivira supports both scenarios by providing comprehensive automation tools that adapt to the specific requirements of initial requests and renewal processes.

How do payer medical policies for Skyrizi differ for inpatient versus outpatient settings, and what should hospitalists consider?

Payer policies often have distinct criteria for inpatient versus outpatient administration, with inpatient often requiring more stringent medical necessity for acute treatment. Hospitalists must ensure documentation clearly justifies the inpatient setting, considering factors like disease severity, need for monitoring, and the patient's overall clinical status, which Klivira helps structure for submission.

What role does the health system's formulary play in Skyrizi prior authorization for hospitalists?

The health system's formulary dictates which medications are preferred or covered, influencing prescribing decisions. While formulary adherence is crucial, prior authorization policies from payers are paramount. Klivira helps navigate these complexities by aligning EMR data with payer-specific requirements, even when a drug is on formulary but still requires PA.